Navigation Links
Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008
Date:8/19/2008

30,764

Stock-Based Compensation Charges:

Cost of revenue, selling and marketing,

research and development, and general

and administrative expenses include

stock-based compensation charges as follows:

Cost of revenue $494 $357 $1,858 $1,205

Selling and marketing $970 $1,055 $4,197 $3,958

Research and development $781 $839 $3,059 $2,448

General and administrative $1,836 $1,604 $7,785 $5,016

Accuray Incorporated

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

June 28, June 30,

2008 2007

Assets

Current assets:

Cash and cash equivalents $36,936 $204,830

Restricted cash 4,830 -

Short-term investments 85,536 -

Accounts receivable, net of allowance

for doubtful accounts of $27 and $20

at June 30, 2008 and 2007,

respectively 33,918 10,105

Inventories 23,047 16,984

Prepaid expenses and other current

assets 6,431 7,937

Deferred cost of revenue - current 31,667 30,709

Total current assets 222,365 270,565

Long-term investments 37,014 -

Property and equipment, net 17,140 23,937

Goodwill 4,495 4,495

Intangible assets, net
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
2. Accuray Announces New Treatment Planning Service Offering
3. Accuray to Present at Citi Investment Research Small & Mid-Cap Conference
4. Accuray Wins Innovations in Healthcare(SM) ABBY Award
5. Accuray Incorporateds CEO to Speak at CitiGroup Healthcare Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DALLAS , July 30, 2015  With over 60,000 customers across the globe, ISN ... helps connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 ... ... ... Headquartered in Dallas, ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... WARSAW, Ind., Sept. 15 Symmetry Medical Inc.,(NYSE: ... the global,orthopedic device industry and other medical markets, announced ... is scheduled to,present at the UBS Global Life Sciences ... City on Thursday, September 25, 2008 at 11:30 a.m. ...
... Corporation,(OTC Bulletin Board: CONX), a worldwide developer and ... call on Thursday, September,25, 2008, at 4:00 PM ... for its fiscal year ended June 30, 2008, ... marketing activities., Corgenix invites all those interested ...
... 15 Epeius Biotechnologies,Corporation today announced that Rexin-G, ... been highlighted in a recent NEWS article,published by ... Sept. 9,2008). The article, authored by Vickie Brower, ... that may succeed where small,molecules and proteins have ...
Cached Biology Technology:Symmetry Medical to Present at UBS Global Life Sciences Conference 2Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... than 200 million years ago, a massive extinction decimated ... end of the Triassic period and the onset of ... dinosaurs to dominate Earth for the next 135 million ... marine and terrestrial species. It,s not entirely clear ...
... gentler chemotherapy drug in the form of nanoparticles has been designed ... woman,s fertility but extra tough on cancer. This is the first ... using a novel in vitro test. ... that predicts the toxicity of a chemotherapy drug to fertility and ...
... WASHINGTON, D.C.--Pit latrines are one of the most common ... on the rise as countries aim to meet the ... evidence supports the use of these basic toilets as ... pit latrines can actually allow disease-causing microbes or other ...
Cached Biology News:Huge and widespread volcanic eruptions triggered the end-Triassic extinction 2Huge and widespread volcanic eruptions triggered the end-Triassic extinction 3Huge and widespread volcanic eruptions triggered the end-Triassic extinction 4New chemo drug gentler on fertility, tougher on cancer 2New chemo drug gentler on fertility, tougher on cancer 3Additional research must be done to ensure safety of pit latrines, new study says 2
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
Biology Products: